MoneyWorks4Me

Unjha Formulations - Quaterly Results

16 May 2025 Evaluate
The sales is pegged at Rs. 24.39 millions for the March 2025 quarter. The mentioned figure indicates a decline of about -45.06% as against Rs. 44.39 millions during the year-ago period.The Net Loss for the quarter ended March 2025 is Rs. -4.07 millions as compared to Net Loss of Rs. -1.76 millions of corresponding quarter ended March 2024Operating profit Margin for the quarter ended March 2025 slipped to -2.59% as compared to 0.71% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 24.39 44.39 -45.06 139.77 185.08 -24.48 139.77 185.08 -24.48
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT -2.59 0.71 -464.79 6.30 5.89 6.96 6.30 5.89 6.96
Interest -0.01 0.50 -102.00 0.08 0.56 -85.71 0.08 0.56 -85.71
PBDT -2.58 0.21 -1328.57 6.22 5.33 16.70 6.22 5.33 16.70
Depreciation 0.33 0.23 43.48 0.98 0.81 20.99 0.98 0.81 20.99
PBT -2.91 -0.02 14450.00 5.24 4.52 15.93 5.24 4.52 15.93
TAX 1.16 1.74 -33.33 1.16 1.74 -33.33 1.16 1.74 -33.33
Deferred Tax -0.01 0.06 -116.67 -0.01 0.06 -116.67 -0.01 0.06 -116.67
PAT -4.07 -1.76 131.25 4.08 2.78 46.76 4.08 2.78 46.76
Equity 44.81 44.81 0.00 44.81 44.81 0.00 44.81 44.81 0.00
PBIDTM(%) -10.62 1.60 -763.90 4.51 3.18 41.64 4.51 3.18 41.64
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..